ArticleScientific reports2025
The effect of postoperative adjuvant chemotherapy on survival outcomes in patients with early stage oral squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Integrating handcrafted and deep learning MRI signatures: an interpretable framework for predicting chemotherapy benefit in glioma.NPJ precision oncology · 2026Article
- In-silico and In-vitro Gene Expression Analysis on Docetaxel and Methotrexate-induced Cytotoxicity in Oral Cancer Cell Line.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The role of adjuvant chemotherapy (Adjuvant CT) in early-stage oral squamous cell carcinoma (OSCC) remains unclear; this study aimed to fill this gap by examining the association between Adjuvant CT and survival outcomes in patients with early-stage OSCC who underwent surgery. A retrospective cohort study was conducted to examine patients diagnosed with early-stage OSCC who underwent surgery between 2004 and 2021. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database for evaluating the survival outcomes of individuals who received Adjuvant CT compared to those who did not. To assess the relationship between Adjuvant CT and survival outcomes, statistical methods, including Cox regression analysis, propensity score matching (PSM), and Kaplan-Meier survival analysis were utilized. A total of 18,532 patients were included, with 2,098 (11.3%) receiving Adjuvant CT. Kaplan-Meier analysis showed that age, sex, tumor site, income level, pathological grade, pT status, neck dissection and radiation were associated with prognosis (P < 0.05). Notably, Adjuvant CT was associated with worse overall survival (OS) and disease-specific survival (DSS) compared to no chemotherapy (5-year OS: 63.1% vs. 72.9%; 10-year OS: 47.6% vs. 57.8%, P < 0.0001; 5-year DSS: 71.3% vs. 85.3%; 10-year DSS: 61.6% vs. 81.7%, P < 0.0001). Consistently, after PSM, Adjuvant CT did not improve outcomes in patients with early-stage OSCC (DSS: P = 0.0001; OS:P = 0.00066). Cox regression analysis indicated no overall survival benefit from Adjuvant CT in early-stage OSCC. However, subgroup analysis suggested potential benefits for patients with poorly differentiated tumors. Our study revealed that postoperative Adjuvant CT provides minimal survival benefits for early-stage OSCC patients, though subgroup signals observed. Although the result of the subgroup analysis show that Adjuvant CT may benefit those with poorly differentiated tumors, further research is needed to identify specific subgroups that may benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.